PARTNERSHIP STRATEGY FOR PHARMA & BIOTECH TEAMS
Often pharma–patient advocacy partnerships are built on funding cycles, not shared purpose. A company funds a program, the organization delivers it, and both sides move on.
The relationship stays narrow, the value stays limited, and the risk of over-reliance on any one partner grows on both sides.
Corporate affairs and patient engagement teams are under real pressure to show more than program delivery. You need partnerships that generate genuine patient insight, hold up as strategic value internally, and strengthen your standing with the communities you work alongside.
APPROACH
The Work
Arete helps pharma and biotech teams build engagement strategies that create real value for advocacy partners while improving your ability to understand and respond to patient needs.
That starts with an honest read of your current partnership portfolio: which relationships are transactional, which have room to become strategic, and where you're carrying more risk than you realize. From there, the work is about building patient advocacy relationships earlier in the product lifecycle, positioning the advocacy organization as a genuine partner rather than a grant recipient, and creating the kind of mutual value that holds up under internal scrutiny.
This is grounded in direct experience with more than a dozen pharma and biotech companies, and in fluency on both sides of the relationship, not just the industry side looking in.
FIT
Who this is for
✓
Corporate affairs, patient engagement, and medical teams whose advocacy partnerships produce funding but limited or emerging strategic value.
✓
Teams entering new therapeutic areas and needing to build credibility with the patient community
✓
Organizations that want an outside, operator-level read on how their engagement strategy actually lands with advocacy partners
✓
Teams under pressure to show strategic return on partnership investment, not just program delivery.
PROOF
Partnership frameworks built with more than a dozen pharma and biotech companies. Direct experience as a Chief Development Officer navigating pharma relationships from the nonprofit side, across multiple therapeutic areas. The differentiator is dual fluency: understanding the strategic needs of the advocacy organization and the pharma partner with equal depth.
BEGIN THE CONVERSATION